Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 94 publications
Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 29, 2025
Patient-reported discordance between care goals and treatment intent in advanced cancer.
Journal: Cancer
Published: April 19, 2025
Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial.
Journal: Communications medicine
Published: December 28, 2024
Racial/Ethnic Disparities in Oncology Clinical Trial Participation: Investigator Attitudes, Needs, and Motivation to Improve.
Journal: JCO oncology practice
Published: November 27, 2024
Creating a Learning Health System in a Cancer Center: Generalizability of an Electronic Health Record Phenotype for Advanced Solid Cancer.
Journal: JCO oncology practice
Published: October 10, 2024
Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial.
Journal: American journal of hematology
Published: May 06, 2024
Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: July 27, 2023
Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: July 21, 2023
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
Journal: Molecular cancer therapeutics
Published: June 09, 2023
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.
Journal: Cancer research communications
Published: May 07, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Journal: Journal for immunotherapy of cancer
Published: March 31, 2023
Last Updated: 09/26/2026